Shashi Gujar

Shashi Gujar.jpg

External WebsiteS:

Shashi Gujar Dalhousie University Profile

Gujar lab website

Research Interests

Dr. Gujar focuses on training our own immune system to fight against diseases. His research program focuses on molecular and immunological aspects of human health, with special focus on cancer immunotherapies. His multi-disciplinary interests include Oncolytic viruses, Immunology and immunotherapies, Epitope discovery, Cell biology & metabolism, Applied immunomics, and Proteo-immuno-metabolomics.

Selected publications (2018-19):

1. Gujar S, Bell J and Diallo JS. 2019. Cancer immunotherapy with oncolytic viruses. Cell. 176(5):1240-1240.

2. Sharif T, Dai C, Martell E, Ghassemi-Rad MS, Hanes M, Murphy P, Kennedy B, Venugopal C, Subapanditha M, Giacomantonio C, Marcato P, Singh S and Gujar S. 2019. TAp73 modifies metabolism and positively regulates growth of cancer stem-like cells in a redox-sensitive manner. Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-17-3177.

3. Murphy P, Yu Q, Konda P, Paolo JA, Jedrychowski M, Kowalewski D, Schuster H, Kim Y, Jain A, Stevanovic S, Gygi S, Mancias J, and Gujar S. 2019. Multiplexed quantitation with isobaric tagging mass spectrometry reveals MHC-I ligand dynamics in response to doxorubicin. Analytical Chemistry. doi: 10.1021/acs.analchem.8b05616.

4. Sharif T, Martell E, Dai K, Singh S and Gujar S. 2019. Regulation of the proline regulatory axis and autophagy modulates stemness in p73 deficient cancer stem-like cells. Autophagy. doi: 10.1080/15548627.2019.1586321.

5. Konda P, Murphy J, and Gujar S. 2019. Improving MHC-I ligand identifications from LC-MS/MS data by incorporating the corresponding peptide motifs. Proteomics. doi: 10.1002/pmic.201800458.

6. Sharif T, Martell E, Dai C, Ghassemi-Rad M, Hanes M, Murphy P, Giacomantonio C, Duncan R, Lee P and Gujar S. 2019. HDAC6 differentially regulates autophagy in stem-like versus differentiated cells. Autophagy. 15(4):686-706.

7. Sharif T, Martell E, Dai C, Saleh M, Kennedy B, Lee P and Gujar S. 2019. Regulation of cancer and cancer-related genes via NAD+. Antioxidants and redox Signaling. Jan 15. doi: 10.1089/ars.2017.7478.

8. Monro S, Colon K, Premadasa L, Roque J, Konda P, Gujar S, Thummel R, Cameron C and McFarland S. 2019. Transition metal complexes and photodynamic therapy: Challenges, opportunities, and highlights from the development of TLD1433. Chemical Reviews. 119(2):797-828.

9. Xu M, Almasi S, Yang Y, Yan C, Sterea A, Shen B, Clements D, Gujar S, Wang J, Zong W, Trebak M, Xu H, El Hiani Y, and Dong X. 2019. The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium. 79:80-88.

10. Almasi S, Sterea A, Clements D, Marcato P, Gujar S and El Hiani Y. 2019. TRPM2 ion channel promotes gastric cancer migration, invasion and tumor growth through the AKT signaling pathway. Scientific Reports. 9(1):4182.

11. Almasi S, Long CY, Sterea A, Clements DR, Gujar S, El Hiani Y. 2019. TRPM2 Silencing Causes G2/M Arrest and Apoptosis in Lung Cancer Cells via Increasing Intracellular ROS and RNS Levels and Activating the JNK Pathway. Cell Physiology and Biochemistry. 2019;52(4):742-757.

12. Gujar S, Pol J, Kim Y, Lee P and Kroemer G. 2018. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends in Immunology (Cell Press). S1471-4906(17)30228-4. [Selected as the cover feature of March 2018 issue of the journal, and also highlighted on Cell.com].

13. Lee P and Gujar S. 2018. Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature Reviews Urology. doi: 10.1038/nrurol. [Featured on the cover page of April 2018 issue of the journal].

14. Murphy P, Giacomantonio M, Paulo J, Everley R, Kennedy B, Pathak G, Clements D, Kim Y, Sharif T, Dai C, Gygi S, and Gujar S. 2018. The NAD+ salvage pathway supports PHGDH-driven serine biosynthesis. Cell Reports. Aug 28;24(9):2381-2391.

15. Pathak GP, Shah R, Kennedy B, Murphy P, Clements D, Giacomantonio M, Xu X, Schlaepfer I and Gujar S. 2018. RTN4 inhibition dysregulates the AKT pathway, destabilizes the cytoskeleton and enhances the efficacy of paclitaxel in cancer cells. Molecular Therapy. Aug 1;26(8):2019-2033.

16. Sharif T, Martell E, Dai C, Ghassemi-Rad M, L Kristen, Weaver I, Singh S and Gujar S. 2018. Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells. Cell Death and Disease. 9(10):990.

17. Gujar S, Pol J and Kroemer G. 2018. Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies. OncoImmunology. doi.org/10.1080/2162.

18. Cruickshank B, Giacomantonio M, Marcato P, Pol J and Gujar S. 2018. Dying to be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy. Frontiers in Immunology. 9:654. doi: 10.3389/fimmu.2018.00654.

19. Almasi S, Kennedy BE, El-Aghil M, Sterea A, Gujar S, Partida-Sánchez S and El Hiani Y. 2018. TRPM2 channel-mediated regulation of autophagy maintains mitochondrial function and promotes gastric cancer cell survival via the JNK signaling pathway. Journal of Biological Chemistry. doi: 10.1074/jbc.M11.

20. Sultan M, Vidovic D, Paine AS, Huynh TT, Coyle KM, Thomas M, Cruickshank BM, Dean C, Clements DR, Kim Y, Lee K, Gujar S, Weaver I and Marcato P. 2018. Epigenetic silencing of TAP1 in Aldefluor+ breast cancer stem cells contributes to their enhanced immune evasion. Stem cells. Jan 17. doi: 10.1002/stem.2780.

21. Warford JR, Lamport AC, Clements DR, Malone A, Kennedy BE, Kim Y, Gujar S, Hoskin DW, Easton AS. 2018. Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis. Acta Neuropathologica Communications. 2018 Jan 4;6(1):4.

22. Pol J, Lévesque S, Workenhe S, Gujar S, Le Boeuf F, Clements D, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, and Galluzzi L. 2018. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology. doi: 10.1080/2162402X.2018.1503032.

23. Yoo B, Khan I, Koomson A, Gowda P, Sasazuki T, Shirasawa S, Gujar S and Rosen K. 2018. Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells. Autophagy. Sep 21:0. doi: 10.1080/15548627.2017.1370171.